Integration of community pharmacies in an Italian colorectal cancer screening program: insights from the Local Health Authority of Bologna

Abstract

In Italy, a nationwide population-based colorectal cancer (CRC) screening initiative has been in place since 2006. In recent years, there has been a growing interest in involving community pharmacies in this activity. This commentary provides an insightful analysis of the integration between the screening program of the Local Health Authority (LHA) of Bologna (Northern Italy) and community pharmacies. A horizontal integration at the micro level with service and clinical integrations supported by meso-level policy (regional authority) was applied. Four types of integration such as normative, informational, financial and functional serving as enablers were implemented. A high level of depth of consensus, connectivity, communication, and trust was pursued. The program achieved large participation from community pharmacies, with 91.1% (n = 234) of pharmacies in the LHA territory actively participating. On average, each pharmacy served 1,228 (range, 1,021-1,519) target citizens. Between 2021 (the first full year under the community pharmacy model) and 2022, pharmacies delivered an annual mean of 68,295 kits (range, 12-840). In 2021, there was a remarkably high level of screening completion, with 93.7% of fecal immunochemical tests being returned to pharmacies. This percentage increased by 3.3% in 2022. In our setting, pharmacy involvement improved service quality by introducing complete traceability of kits and specimen flow, as well as temperature control. It also led to a 4.6% increase in attendance rates compared to the previous organizational model (61.6% vs. 57%; P < 0.001). Finally, additional European experiences involving community pharmacies in organized CRC screening programs, resembling the Bologna setting, are reported.

Keywords

Population-based colorectal cancer screening program / community pharmacy / integration / organizational choices / service quality

References

[1] Gupta S.Screening for colorectal cancer.Hematol Oncol Clin N Am2022;36:393-414 PMCID:PMC9167799

[2] Senore C,de Jonge L.Rationale for organized colorectal cancer screening programs.Best Pract Res Clin Gastroenterol2023;66:101850

[3] Ogunwobi OO,Akingboye A.Biomarkers in colorectal cancer: current research and future prospects.Int J Mol Sci2020;21:5311 PMCID:PMC7432436

[4] Saeed O,Fisher KW.RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications.J Clin Pathol2019;72:135-9

[5] Bylsma LC,Garawin TA.Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis.Cancer Med2020;9:1044-57 PMCID:PMC6997095

[6] Gawiński C,Mróz A.Correlation between lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and tumor-infiltrating lymphocytes (TILs) in left-sided colorectal cancer patients.Biology2022;11:385 PMCID:PMC8945266

[7] Sur D,Braithwaite D.MicroRNA panels as diagnostic biomarkers for colorectal cancer: a systematic review and meta-analysis.Front Med2022;9:915226 PMCID:PMC9676370

[8] Li X,Zeng J.Heterogeneous expression of mismatch repair proteins and interpretation of immunohistochemical results in colorectal cancer and endometrial cancer.Pathol Res Pract2023;248:154647

[9] Shia J.Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.J Mol Diagn2008;10:293-300 PMCID:PMC2438196

[10] Adeleke S,Choy A.Microsatellite instability testing in colorectal patients with lynch syndrome: lessons learned from a case report and how to avoid such pitfalls.Per Med2022;19:277-86

[11] Wools A,de Leeuw JR.Colorectal cancer screening participation: a systematic review.Eur J Public Health2016;26:158-68

[12] Mancini S,Falcini F.Strategies for delivery of faecal occult blood test kits and participation to colorectal cancer screening in the Emilia-Romagna region of Italy.Eur J Cancer Care2018;27:e12631

[13] Decreto del Presidente del Consiglio dei Ministri 12 Gennaio 2017. Definizione e aggiornamento dei livelli essenziali di assistenza, di cui all'articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n. 502. (17A02015) (GU Serie Generale n.65 del 18-03-2017 - Suppl. Ordinario n. 15). Available from: https://www.gazzettaufficiale.it/eli/id/2017/03/18/17A02015/sg [Last accessed on 20 Feb 2024].

[14] EpiCentro-Istituto Superiore di Sanità. Sorveglianza PASSI. Screening colorettale. Indicatori - PASSI 2021-2022. Available from: https://www.epicentro.iss.it/passi/dati/ScreeningColorettale [Last accessed on 20 Feb 2024].

[15] Masseria C.Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment.Eur J Health Econ2010;10 Suppl 1:S41-9

[16] Bucchi L,Baldacchini F.Emilia-Romagna Region Workgroup for Colorectal Screening EvaluationHow a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study.Br J Cancer2022;127:541-8 PMCID:PMC9345854

[17] Karsa L, Patnick J, Segnan N; European Commission, Directorate-General for Health and Consumers, Executive Agency for Health and Consumers, World Health Organization. European guidelines for quality assurance in colorectal cancer screening and diagnosis. In: Karsa L, Patnick J, Segnan N, editors. Organisation. Luxembourg: Publications Office of the European Union; 2010. p. 50. Avaliable from: https://op.europa.eu/en/publication-detail/-/publication/e1ef52d8-8786-4ac4-9f91-4da2261ee535 [Last accessed on 23 Feb 2024].

[18] Lindsey L,Nazar H.Promoting the early detection of cancer: a systematic review of community pharmacy-based education and screening interventions.Cancer Epidemiol2015;39:673-81

[19] Santolaya M,Grau J.Evaluating the appropriateness of a community pharmacy model for a colorectal cancer screening program in Catalonia (Spain).J Oncol Pharm Pract2017;23:26-32

[20] Thomson K,Walton N,Bambra C.The effects of community pharmacy-delivered public health interventions on population health and health inequalities: a review of reviews.Prev Med2019;124:98-109

[21] Della Valle PG,Battisti F.The community pharmacy model for colorectal cancer screening: policy insights from a national programme.Res Soc Adm Pharm2023;19:1595-601

[22] Chiereghin A,Pizzi L,Roti L.Applying the healthcare failure mode and effects analysis approach to improve the quality of an organised colorectal cancer screening programme. J Med Screen 2023.

[23] Urionagüena A,Gastelurrutia MÁ.Community pharmacy and primary health care - types of integration and their applicability: a narrative review.Res Soc Adm Pharm2023;19:414-31

[24] Hirst Y,Kerrison RS.Text-message reminders in colorectal cancer screening (TRICCS): a randomised controlled trial.Br J Cancer2017;116:1408-14 PMCID:PMC5520096

[25] EpiCentro-Istituto Superiore di Sanità. Gli screening oncologici e l’impatto della pandemia: i dati dalla sorveglianza PASSI. Available from: https://www.epicentro.iss.it/passi/focus/screening-oncologici-impatto-pandemia-dati-passi-2020 [Last accessed on 20 Feb 2024].

[26] Vives N,Binefa G.Role of community pharmacies in a population-based colorectal cancer screening program.Prev Med2021;145:106420

[27] Burón A,Andreu M.Colorectal cancer early screening program of Barcelona, Spain: indicators of the first round of a program with participation of community pharmacies.Med Clin2015;145:141-6

[28] Prentice A,Vance M.Colorectal cancer screening and the role of community pharmacy.Pharm J2019;302:7921

[29] National Institute for Health and Care Excellence. Community pharmacies: promoting health and wellbeing. NICE guideline [NG102]. 2018. Available from: https://www.nice.org.uk/guidance/ng102 [Last accessed on 20 Feb 2024].